FGF20 and Parkinson's disease: No evidence of association or pathogenicity via α-synuclein expression

Christian Wider, Justus C. Dachsel, Alexandra I. Soto, Michael G. Heckman, Nancy N. Diehl, Mei Yue, Sarah Lincoln, Jan O. Aasly, Kristoffer Haugarvoll, John Q. Trojanowski, Spiridon Papapetropoulos, Deborah Mash, Alex Rajput, Ali H. Rajput, J. Mark Gibson, Timothy Lynch, Dennis W. Dickson, Ryan J. Uitti, Zbigniew K. Wszolek, Matthew J. FarrerOwen A. Ross

Research output: Contribution to journalLetterpeer-review

36 Scopus citations

Abstract

Genetic variation in fibroblast growth factor 20 (FGF20) has been associated with risk of Parkinson's disease (PD). Functional evidence suggested the T allele of one SNP, rs12720208 C/T, altered PD risk by increasing FGF20 and α-synuclein protein levels. Herein we report our association study of FGF20 and PD risk in four patient-control series (total: 1,262 patients and 1,881 controls), and measurements of FGF20 and a-synuclein protein levels in brain samples (nine patients). We found no evidence of association between FGF20 variability and PD risk, and no relationship between the rs12720208 genotype, FGF20 and α-synuclein protein levels.

Original languageEnglish (US)
Pages (from-to)455-459
Number of pages5
JournalMovement Disorders
Volume24
Issue number3
DOIs
StatePublished - Feb 15 2009

Keywords

  • Association study
  • FGF20
  • Genetics
  • Parkinson's disease
  • α-Synuclein

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'FGF20 and Parkinson's disease: No evidence of association or pathogenicity via α-synuclein expression'. Together they form a unique fingerprint.

Cite this